SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

CTSO

Cytosorbents Corp
NEUTRAL
Impact 4/10
Horizonmonths Processed8d 23h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor the German sales recovery and the timing of the DrugSorb-ATR De Novo submission to FDA in early 2027. Cash runway remains tight at $5.7M, so any delay in revenue growth or regulatory milestones could increase financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CTSO drug pipeline →

CytoSorb

▼ Bearish Named in this press release
Impact
Phase
Approved / Commercialized
Time to market
Already on the market (CE-marked in Europe, FDA-cleared in US)
Next catalyst
None dated

What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$4.87
T+0 close · Nov 12, 2026 · via day close
Latest settled
−14.58%
T+5 · $4.16
Vs SPY
−6.02%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 13 $4.87entry
  2. T+1 · 6d ago −0.41%α +1.50% · $4.85
  3. T+5 · 2d ago −14.58%α −6.02% · $4.16
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CytoSorbents reported Q3 2026 revenue of $9.7M (+3% YoY), slightly below the $9.9M consensus, and a GAAP net loss of $0.58 per share, which was narrower than the $-0.90 consensus estimate. The company achieved operating cash flow breakeven (excluding restructuring payments), a key milestone, but revenue growth remains modest and the German market declined 20% YoY.

Key Financial Metrics

EPS
−$0.58
est −$0.90 · +35.6%
Revenue
$9.7M
est $9.9M · -2.0% · +3.0% YoY
Rating
in line
Gross Margin
75%

Key Facts

  • Revenue $9.7M, +3% YoY vs $9.5M (consensus $9.9M)
  • GAAP net loss $0.58 per share vs consensus $-0.90 (narrower loss)
  • Operating cash flow positive $43K (excluding $251K restructuring payments), achieving breakeven target
  • Gross margin improved to 75% from 70% a year ago
  • Germany sales declined 20% YoY, representing 24% of quarterly sales
  • Cash and restricted cash $5.7M at quarter end
  • Adjusted EBITDA loss narrowed 86% to $0.3M

Financial Impact

Revenue $9.7M, net loss $1.8M, operating cash flow $43K positive (ex-restructuring)

revenuenet lossoperating cash flowgross margin

Risk Factors

  • Revenue growth of only 3% YoY, below consensus estimate
  • Germany sales declined 20% YoY, a key market
  • Cash position $5.7M may require additional financing before breakeven is sustained
  • Regulatory approval for DrugSorb-ATR is uncertain and subject to FDA review

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302938462

Track record

12 reports on CTSO

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20261d ago 424B5 Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  2. Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  3. Nov 19, 20263d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
  4. Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
  5. Nov 12, 20269d ago Press Release Neutral 4/10 Viewing Entry $4.87 Now $4.16 −14.58% settles Feb 11
  6. Nov 12, 20269d ago 8-K Neutral 5/10 No price data
  7. Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
  8. Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
  9. Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
  10. Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026